OncoMatch/Clinical Trials/NCT03909412
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
Is NCT03909412 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Carfilzomib and Cyclophosphamide for multiple myeloma.
Treatment: Carfilzomib · Cyclophosphamide · Dexamethasone · Granulocyte Colony-Stimulating Factor — This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor (carfilzomib)
Subject previously received treatment with Carfilzomib.
Must have received: induction therapy
Subjects must have completed any 'induction therapy' and have achieved less than a CR.
Cannot have received: stem cell transplant
Subject has had prior mobilization or stem cell transplant.
Cannot have received: radiation therapy
Exception: Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.
Subject has received radiation therapy within 3 weeks of enrollment.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1000 cells/mm3 (≥500 for patients with bone marrow biopsy displaying >50% involvement by myeloma); Platelets count ≥ 50,000/mm3 (≥ 30,000 for patients with bone marrow biopsy displaying >50% involvement by myeloma); Hemoglobin > 9.0 g/dL
Liver function
Serum SGOT/AST <3.0 x ULN; Serum SGPT/ALT <3.0 x ULN; Serum total bilirubin <1.5 x ULN
Cardiac function
MUGA scan or echo with LVEF ≥40% within 6 months of enrollment
Absolute neutrophil count (ANC) ≥1000 cells/mm3 (≥500 for patients with bone marrow biopsy displaying >50% involvement by myeloma); Platelets count ≥ 50,000/mm3 (≥ 30,000 for patients with bone marrow biopsy displaying >50% involvement by myeloma); Hemoglobin > 9.0 g/dL; Serum SGOT/AST <3.0 x ULN; Serum SGPT/ALT <3.0 x ULN; Serum total bilirubin <1.5 x ULN; MUGA scan or echo with LVEF ≥40% within 6 months of enrollment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hackensack Meridian Health - John Theurer Cancer Center · Hackensack, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify